Nintedanib Goibela

Nintedanib, the active ingredient in Nintedanib Goibela, is a tyrosine kinase inhibitor presented as a capsule for oral use. It is indicated for idiopathic pulmonary fibrosis, systemic sclerosis‑associated interstitial lung disease, and in combination with chemotherapy for non‑small cell lung cancer in appropriate patients.

GNH USA supplies Nintedanib Goibela as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The product is manufactured for the European Union market and meets EU quality standards.

Nintedanib is used in fibrotic lung diseases and as part of cancer therapy, targeting pathways that drive fibroblast activity and tumor angiogenesis.

Idiopathic pulmonary fibrosis: slows disease progression and reduces decline in lung function. Systemic sclerosis‑associated interstitial lung disease: limits fibrosis and preserves respiratory capacity. Non‑small cell lung cancer (in combination with chemotherapy): enhances antitumour effect by inhibiting angiogenesis.

Nintedanib may cause a range of adverse reactions, which are grouped by frequency and severity.

Common Side Effects: - Nausea - Diarrhoea - Vomiting - Decreased appetite - Abdominal pain - Headache

Serious or Rare Side Effects: - Elevated liver enzymes (ALT/AST) - Bleeding events, including haemoptysis - Arterial thrombotic events such as myocardial infarction - Gastrointestinal perforation - Severe infections - Life‑threatening skin reactions (e.g., Stevens‑Johnson syndrome).

When prescribing Nintedanib, clinicians should observe several safety measures to minimise risk.

Monitor liver function: obtain baseline and periodic LFTs during therapy. Assess bleeding risk: evaluate concomitant anticoagulant or antiplatelet use. Evaluate cardiovascular status: watch for hypertension or arterial events. Avoid use in severe hepatic impairment: contraindicated in patients with Child‑Pugh C liver disease. Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Nintedanib can interact with other medicines, requiring attention to avoid clinically significant effects.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase nintedanib exposure. - Anticoagulants (e.g., warfarin): heightened risk of bleeding. - High‑dose aspirin or other antiplatelet agents: increased bleeding tendency.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., fluconazole): may raise plasma levels. - P‑gp inhibitors (e.g., verapamil): could affect absorption. - Diuretics: monitor electrolytes and renal function. - Antifungal agents (e.g., itraconazole): may increase systemic exposure.